VENTOLIN (salbutamol) - Asthma
Opinions on drugs -
Posted on
Jan 09 2025
Reason for request
First listing
Summary of opinion
Favourable opinion for reimbursement of the range supplement VENTOLIN (salbutamol) 0.5 mg/1 ml solution for subcutaneous injection in ampoules packaged in packs of 5 ampoules in the MA indication, i.e.: “Symptomatic treatment of acute asthma in adults by subcutaneous injection”.
No clinical added value of the new form (pack of 5 ampoules) compared to the form already available (pack of 6 ampoules).
Clinical Benefit
Substantial |
The Committee deems that the clinical benefit of VENTOLIN (salbutamol) 0.5 mg/1 ml solution for subcutaneous injection in ampoules in a pack of 5 is substantial in the MA indication. |
Clinical Added Value
no clinical added value |
This medicinal product is a range supplement that does not provide any clinical added value (CAV V) compared to the form already listed. |
Documents
English version
Contact Us
Évaluation des médicaments